Skip to main content

Talk Bio

Search This Blog

Valar Labs scores FDA breakthrough tag for AI‑based bladder cancer risk test

on May 18, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Valar Labs received FDA Breakthrough Device Designation for its AI‑powered bladder cancer risk test, Vesta Bladder Risk Stratify Dx, marking it as the first AI‑based digital pathology prognostic test in bladder cancer to earn this status.

The test analyzes routine hematoxylin and eosin (H&E) stained pathology slides to generate a risk stratification that helps clinicians decide on treatment intensity and earlier interventions.

Breakthrough designation is not a marketing approval but accelerates FDA review and interaction, with the goal of faster eventual clearance and patient access.

Vesta is already clinically available as a lab‑developed test for bladder cancer and is being expanded to other cancers such as prostate and pancreatic.

Sources:

Valar Labs hits US first with breakthrough designation for AI bladder ...

Announcing Our $22 Million Series A to Accelerate AI in Precision ...

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI…

Valar Labs Receives FDA Breakthrough Device Designation for ...

Analyzing the tumor to predict cancer treatment response

Valar Labs Announces $22 Million Series A to Advance Vesta, First AI Diagnostic Test to Predict Treatment Response in Bladder Cancer, and Catalyze Expansion in Other Cancers - Silicon UK

Vesta Bladder | Valar Labs

Valar Labs' CHAI Biomarkers Validated in New Study ...

Valar Labs' CHAI Biomarkers Validated in New Study in European Urology for Predicting Outcomes of High Grade Ta Bladder Cancer

Valar Labs Wins FDA Breakthrough Tag for AI Bladder Cancer Tool

Bladder cancer - BioSpace

Valar Labs | Predicting Response to Intravesical BCG in High-Risk NMIBC Using an Artificial Intelligence–Powered Pathology Assay: Development and Validation in an International 12-Center Cohort

Valar Labs Receives FDA Breakthrough Device Designation for ...

FDA Grants Breakthrough Device Designation to TOBY's ... - MedPath

Valar Labs Receives FDA Breakthrough Device Designation for Vesta Bladder Risk Stratify Dx

Bladder Risk Breakthrough Device Designation digital pathology prognostic test hematoxylin and eosin ( H&E ) stained Stratify Dx United States Food and Drug Administration Valar Labs Vesta <beetles>

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Xaira Therapeutics Launches X-Cell: First AI Virtual Cell Model Testing Scaling Laws on Massive Perturbation Data

Xaira Therapeutics announced X-Cell on March 17, 2026, a 4.9-billion-parameter diffusion language model, the largest virtual cell model to date, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset with 25.6 million perturbed single-cell transcriptomes across seven diverse contexts. 1 2 X-Cell predicts cell responses to genetic perturbations, outperforming existing models by up to five-fold on metrics like Pearson delta, and generalizes zero-shot to unseen biological contexts such as iPSC-derived melanocyte progenitors and primary human CD4+ T cells. 1 2 The model follows power-law scaling dynamics similar to large language models, using a novel diffusion architecture that iteratively refines predictions. 2 Xaira, founded in 2024 with over $1 billion funding, plans to expand X-Atlas to primary cells, organoids, and in vivo perturbations, focusing on inflammatory/immunological diseases and antibody therapeutics. 1 3 A subset of the Pisces dataset and X-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC